Sucunamostat is under clinical development by Scohia Pharma and currently in Phase I for Nephrotic Syndrome. According to GlobalData, Phase I drugs for Nephrotic Syndrome have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sucunamostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sucunamostat overview

Sucunamostat (SCO-792) is under development for the treatment of diabetic kidney disease, phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria (HCU), nephrotic syndrome and albuminuria. The drug is administered through oral route. It acts by targeting enteropeptidase enzyme.

The drug candidate was under development for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH) and chronic kidney disease. 

Scohia Pharma overview

Scohia Pharma (Scohia) is a drug discovery company that discovers and develops novel therapies for lifestyle-related diseases including cardiovascular, metabolic, and renal disease. It conducts research for medicinal chemistry, pharmacology, and clinical development; and develops products for partner companies. The company’s pipeline includes a wide range of drug candidates to treat diabetic kidney disease, hypertension, phenylketonuria, maple syrup urine disease, homocystinuria, nephrotic syndrome, diabetes, obesity, nonalcoholic steatohepatitis (NASH), infertility, alopecia, and among others. It is also developing small molecules and peptide-based drugs for rare endocrine diseases, lymphoedema, and other indications. Scohia is headquartered in Fujisawa, Kanagawa, Japan.

For a complete picture of Sucunamostat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.